AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05432271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to healthy labels only
Description: Green labels only for beverages and foods scored as healthy
Study NCT05432271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to healthiness information
Description: All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
Study NCT05432271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to physical activity equivalents
Description: All beverages and foods labeled with physical activity required to burn their calories
Study NCT05432271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to high in nutrient warning labels
Description: Warning labels only for beverages and foods that exceed the thresholds for sugar, sodium, saturated fat, or calorie content
Study NCT05464290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NANOfat grafting
Description: The nanofat in a 10 cc syringe connected with a 23 gauge needle is then used to create a lot of tunnels in the plane of the sclerotic tissues and the nanofat is delivered into the tunnels. During injection the area is massaged to achieve complete releasing of fibrous tissue that was feel under the fingers.
Study NCT04090996 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual TAsk
Description: Motor assessment includes:~* posturographic examination in Single-task (ST) and Double-task (DT)~* an analysis of ST and DT walking;~* Timed Up and Go (TUG) performances in real (rTUG) and imagined (iTUG) versions;
Study NCT06349720 — intervention group
Intervention type: BEHAVIORAL
Intervention: respiratory rehabilitation
Description: Emote respiratory rehabilitation:Patients wear monitoring devices and upload real-time monitoring data such as vital signs through the FREE rehabilitation app installed on their personal phones. Medical staff monitor changes in patients' vital signs in real time through the FREE rehabilitation app on the medical end, and adjust respiratory rehabilitation plans based on their phone or video guidance.~Outpatient respiratory rehabilitation:Traditional outpatient respiratory rehabilitation is based on a group approach, with individualized intensity determined based on baseline assessment results, and is conducted under supervision twice a week for a period of 12 weeks.
Study NCT04787601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cognıtıve-based neuromuscular exercıses will be applied.
Study NCT04787601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic Training
Description: Classic match preparation training
Study NCT04787601 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classic Training
Description: Classic match preparation training
Study NCT05274074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social LEAF
Description: Social LEAF is an adaptation of the Life Enhancing Activities for Family Caregivers program to focus on social relationships and loneliness. Social LEAF is a six-session group program provided by video-conference that teaches caregivers coping skills to improve social relationships and social connection. Social LEAF is delivered in groups of up to 10 caregivers via videoconference and will consist of six weekly hour-long discussion-based classes to teach positive coping skills around improving social relationships. Each week will focus on a skill from the original LEAF study adapted to the group and social context.
Study NCT06533033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid Release Capsules Melatoni
Description: Twenty-five will be given melatonin therapy in combination with the conventional treatment.~2 tablets,30 minutes before sleeping once daily for 8 weeks.
Study NCT06533033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide ointment, Kenacort-A orabase
Description: Twenty-five will be given topical corticosteroid applied twice to three times daily.~Topical antifungal will be applied three to four times daily. This conventional treatment will be given to the patients for 8 weeks
Study NCT05368220 — intervention group
Intervention type: OTHER
Intervention: Whole genome sequencing
Description: Each participant will have WGS performed in order to report on clinically actionable genetic variation in diabetes.
Study NCT06171542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTM Injection
Description: All glenohumeral joint injections will be performed by a physician under the guidance of either ultrasound or fluoroscopy to ensure and document intra-articular needle placement. 2cc of CTM Flow will be injected. The glenohumeral joint will be injected with the medication under the discretion of the treating surgeon.
Study NCT05949723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Golf simulator device
Description: The golf simulator can accurately predict the flight trajectory and landing point of the ball using high-speed moving object measurement technology, giving the user the impression that they are playing on a real golf course.
Study NCT05554952 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: Mineral trioxide aggregate (MTA) is composed of Portland cement, with 4:1 addition of bismuth oxide added so that the material can be detected on a radiograph. The cement is made up of calcium, silicon and aluminium. The main constituent phases are tricalcium and dicalcium silicate and tricalcium aluminate.
Study NCT05817851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)
Description: in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.
Study NCT05817851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.
Study NCT05885022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calibreye System
Description: Implantation of a glaucoma device to reduce intraocular pressure
Study NCT04950374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizer Body Lotion
Description: The body lotion product is a moisturizing formulation intended for topical use on the whole body and face. It will be applied at least twice daily.
Study NCT04950374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lip Moisturizer
Description: The lip product is a moisturizing formulation intended for topical use on the lips. It will be applied at least twice daily.
Study NCT06368765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution (ORS)
Description: Participants will be administered the ORS during one of the study visits
Study NCT06368765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participants will be administered water during one of the study visits
Study NCT05755308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous FMT
Description: Autologous faecal microbiota transplantation by colonoscopy.
Study NCT05755308 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FMT
Description: Placebo FMT will consist of 250 mL water. Placebo infusions will be delivered by colonoscopy.
Study NCT06157281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect
Description: A multicomponent, clinic-level intervention consisting of strategies aimed at improving retention and viral load suppression by enhancing the patient and staff experience.
Study NCT06191718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Valve Replacement
Description: Foldax Mitral Valve Replacement
Study NCT04808804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography (OCT)
Description: a noninvasive imaging technology used to obtain high resolution cross-sectional images of the retina
Study NCT05309278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Older adults assigned to this group will undergo two weekly sessions of remote and supervised physical training at home for 1 hour on non-consecutive days. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
Study NCT05309278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Older adults assigned to this group will undergo two weekly sessions of remote and supervised physical training at home for 1 hour on non-consecutive days. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
Study NCT05309278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: These participants will also perform a weekly remote and supervised cognitive training session with neurobic exercises for 1 hour. In addition to the supervised cognitive training session, participants will also be prescribed asynchronous neurobic exercises to be performed on the remaining days of the week (without supervision). The intervention will last for 12 weeks, and all asynchronous neurobic exercises will be recorded in the following synchronous sessions by the supervisor. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
Study NCT06279325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive stimulation program
Description: * The cognitive stimulation (CS) program, for the IG, will be previously designed by 2 Occupational Therapy (OT) of the team, and adapted to the computerized format through a platform specialized in cognitive neurorehabilitation. The activities will be designed under OT models: human occupation model and cognitive-perceptual model, so that the different professions, interests and roles are represented, and allow to express different levels of complexity, according to the level of Cognitive Reserve (CR).~* The cognitive aspects to be worked on are: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.~* In addition, reinforcement, EF, episodic memory, attention and information processing speed activities will be designed, also according to the CR level.
Study NCT06279325 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face training-explanatory session
Description: The CG will undergo a group and face-to-face training-explanatory session, where the importance of maintaining the usual level of cognitive activity will be emphasized.
Study NCT04672941 — intervention group
Intervention type: DRUG
Intervention: Tiotropium bromide plus Olodaterol
Description: Tiotropium bromide plus Olodaterol
Study NCT06542536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monlunabant
Description: Oral monlunabant
Study NCT06542536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (monlunabant)
Description: Oral placebo (monlunabant)
Study NCT05307848 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06580873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOVATO
Description: HIV-1 medication
Study NCT05828966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin (hCG)
Description: H.C.G. will be given in Group A and in a dose of 5000units intramuscular injection followed by a drip of 10,000 units in 500ml of dextrose 5%, at the rate of 20 drops per minute.
Study NCT05828966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: 4gm of MgSO4 will be given in Group B as intravenously as continuous dose followed by 2gm/hr till uterine quiescence is achieved.
Study NCT06472466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep/eating virtual reality self-help exposure-based intervention
Description: Participants will receive one of two possible interventions:~1. A virtual reality kitchen with foods with different caloric contents. Participants will be invited to explore the environment and interact with the stimuli they feel most comfortable with. Depending on their preference, they will be able to access the virtual kitchen in one of three different conditions: alone, accompanied by a pink elephant (designed to induce positive mood), or accompanied by a reassuring voice that will encourage them to interact with the food and face their fears.~2. A virtual reality bedroom with several objects, some of which will have a neutral valence for people with sleep difficulties, and others that will be related to insomnia, such as a mobile phone, electronic devices and a clock marking 3:00. Participants will be first told to move in the environment and they could not fall asleep. Then, they will receive specific instructions to cope with sleeping difficulties.
Study NCT06472466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep/eating self-help written materials.
Description: Participants allocated to the control condition will be invited to download self-help written materials about eating and sleep difficulties and helpful ways to cope with these.
Study NCT01438502 — intervention group
Intervention type: DRUG
Intervention: HyperHAES® (hypertonic saline/HES)
Description: After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
Study NCT05066230 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
Study NCT06236750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPIFIX
Description: EPIFIX® is an allograft derived from dehydrated human amnion/chorion membrane. EPIFIX is a medical device in Japan (Generic name: Material using human amniotic membrane for promotion of tissue healing) for use on intractable ulcers that are non-responsive to existing therapies for the purpose of promoting wound healing.
Study NCT05776173 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BD211
Description: Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
Study NCT05668533 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene versus PENG Block
Description: 1. Interscalene group: Patients received ipsilateral ultrasound-guided interscalene nerve after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).~2. PENG Block: Patients received ultrasound-guided PENG block after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).
Study NCT06192329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hot water therapy
Description: On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 105°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
Study NCT06192329 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Warm water immersion
Description: On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 97°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
Study NCT06578403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: external microneedling
Description: external micro_needling
Study NCT06578403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: minimally invasive non- surgical periodontal therapy
Description: minimally invasive non- surgical periodontal therapy
Study NCT06578403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: minimally invasive non- surgical periodontal therapy
Description: minimally invasive non- surgical periodontal therapy
Study NCT06578403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal micro_needling
Description: internal micro_ needling
Study NCT05203796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous pulsed electrical stimulation (NuEyne 02)
Description: Arm 1: Experimental: Experimental group: Dry eye disease patients (n=12) Device: Pulse Electrical Stimulation Pulse Electrical Stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
Study NCT05203796 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Arm 2: Sham Comparator: Comparison group: Dry eye disease patients (n=12) Device: Sham stimulation Sham stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
Study NCT05931042 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)
Study NCT06578533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: The recommended starting dose of Lokelma is 10 g, administered three times a day.~If, at any time during the study, sK is > 6.5 mEq/L, treatment for acute hyperkalemia will be started following common clinical practice and local protocols, and investigator will consider RAASi / MRA withdrawal, or downtitration. In this case (confirmed sK > 6.5 mEq/L despite the maximum SZC dose) patient will leave the IP and will be counted as a treatment failure.~If sK is ≤ 3.0 mEq/L, discontinue SZC. The subject should immediately receive appropriate medical intervention.~If sK is between 3.1-5.1 mEq/L, pause SZC and re-evaluate in a week. This one-week SCZ treatment temporary discontinuation can only be applied once; if a new sK value between 3.1-5.1 mEq/L is detected, patient will leave the IP permanently.~Depending on the serum potassium levels at each visit, the dose of SZC will be adjusted.
Study NCT06575907 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04959981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-007
Description: Administered orally
Study NCT04959981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERAS-601
Description: Administered orally
Study NCT05953337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYE90 Microspheres Treatment
Description: Y90 glass microspheres
Study NCT05853887 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: iNUDGE
Description: Electronic health record nudge which prompts physicians to order plasma-based NGS testing for eligible patients with newly diagnosed lung cancer.
Study NCT04959981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered orally
Study NCT04959981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Administered orally
Study NCT05911503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Ganciclovir Eye Drops
Description: Administration method and dosage adjustment: 2% ganciclovir eye drops, 10 times/day for two weeks, 8 times/day for two weeks, 6 times/day for two weeks, 4 times/day for more than 6 weeks
Study NCT06321081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan, cetuximab, envafolimab
Description: rechallenge treatment
Study NCT04517656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: A peripheral blood sample will be taken and will include 2 EDTA tubes of 5 mL, for a total volume of 10 mL:~* Samples before the allograft,~* Samples at different times post-allograft: 15 days, 30 days, 60 days, 90 days, 180 days, 360 days,~* Samples in the event of the occurrence of concomitant events during the 12-month follow-up period: occurrence of acute Graft Versus Host Disease, chronic Graft Versus Host Disease, or relapse of the disease before the initiation of a new treatment.
Study NCT06200454 — intervention group
Intervention type: DEVICE
Intervention: neuromuscular ultrasound of cranial nerves
Description: neuromuscular ultrasound of cranial nerves.
Study NCT04973969 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decapeptyl
Description: diagnosis of predictio value
Study NCT05138770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets
Description: VC005 Tablets 1、5、10、25、50、100mg single dose
Study NCT05138770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VC005 Tablets Placebo
Description: VC005 Tablets Placebo 1、5、10、25、50、100mg single dose
Study NCT05138770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets food effects group
Description: VC005 Tablets qd per period, for two periods
Study NCT05250570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)
Description: This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) to assist individuals in tolerating benzodiazepine withdrawal symptoms and teaching skills to prevent relapse to benzodiazepine use. It will also provide psychoeducation about benzodiazepine use in OAT. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.